<DOC>
	<DOCNO>NCT01653158</DOCNO>
	<brief_summary>This clinical trial design determine safety , tolerability , pharmacokinetics pharmacodynamic effect escalate dos CP 751,871 give combination docetaxel patient non-hematologic malignancy docetaxel reasonable treatment option .</brief_summary>
	<brief_title>CP-751,871 In Combination With Docetaxel In Advance Non-hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Age great 18 year Documented advancedstage nonhematologic malignancy docetaxel monotherapy reasonable treatment option Eastern Cooperative Oncology Group [ ECOG ] performance status 01 Significant active cardiac disease Chemotherapy , biological investigational agent within 4 week prior dose Inadequate bone marrow , renal , cardiac liver function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>non-hematologic cancer</keyword>
	<keyword>advanced solid tumor</keyword>
	<keyword>prostrate cancer</keyword>
</DOC>